Paula Green Sells 632 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 632 shares of Twist Bioscience stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $18,802.00. Following the completion of the sale, the senior vice president now directly owns 128,748 shares in the company, valued at approximately $3,830,253. This represents a 0.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Paula Green also recently made the following trade(s):

• On Monday, May 5th, Paula Green sold 1,101 shares of Twist Bioscience stock. The stock was sold at an average price of $37.65, for a total value of $41,452.65.
• On Wednesday, April 2nd, Paula Green sold 140 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total transaction of $5,422.20.
• On Thursday, March 20th, Paula Green sold 291 shares of Twist Bioscience stock. The shares were sold at an average price of $41.68, for a total transaction of $12,128.88.
• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38.

Twist Bioscience Stock Down 3.7%

Shares of NASDAQ:TWST traded down $1.08 during trading hours on Wednesday, hitting $28.33. The company's stock had a trading volume of 1,142,745 shares, compared to its average volume of 978,754. The firm's fifty day moving average price is $35.90 and its 200 day moving average price is $42.50. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -8.38 and a beta of 2.54. Twist Bioscience Co. has a 52 week low of $27.12 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. As a group, research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, May 6th. Robert W. Baird lowered their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays dropped their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. cut their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $50.40.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Strs Ohio acquired a new stake in Twist Bioscience in the 1st quarter valued at about $711,000. Intech Investment Management LLC lifted its holdings in shares of Twist Bioscience by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after acquiring an additional 4,591 shares during the last quarter. Bayforest Capital Ltd boosted its position in shares of Twist Bioscience by 49.3% during the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock worth $191,000 after buying an additional 1,604 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock valued at $36,629,000 after purchasing an additional 37,577 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.